- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03752658
TAF Real World Study for Universal Effectiveness (TRUE)
A Real-world Clinical Study on Effectiveness and Safety of Long-term TAF Treatment in Chronic Hepatitis B Patients in China
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Qin Ning, MD., Ph.D.
- Telefonnummer: +86 278366 2391
- E-post: qning@vip.sina.com
Studera Kontakt Backup
- Namn: Di Wu, MD., Ph.D.
- Telefonnummer: +86 278366 2391
- E-post: woody_1984@163.com
Studieorter
-
-
-
Hangzhou, Kina
- Rekrytering
- Shulan(Hangzhou) hospitai
-
Kontakt:
- Zhe Yu
-
Huvudutredare:
- Zhe Yu
-
Nanchang, Kina
- Rekrytering
- First Affiliated Hospital of Nanchang University
-
Kontakt:
- Xiaoping Wu, Doctor
-
Shanghai, Kina
- Rekrytering
- Shanghai public health clinic
-
Kontakt:
- Liang Chen
-
Huvudutredare:
- Liang Chen
-
Wuhan, Kina
- Har inte rekryterat ännu
- General Hospital of The Yangtze River Shipping
-
Kontakt:
- Lvye Xu
-
Huvudutredare:
- Lvye Xu
-
Wuhan, Kina
- Rekrytering
- The Seventh Hospital of Wuhan
-
Kontakt:
- Youqin Yan
-
Huvudutredare:
- Youqin Yan
-
Xiangya, Kina
- Rekrytering
- Xiangya Hospital of Central South University
-
Huvudutredare:
- Yan Huang
-
-
Hubei
-
Wuhan, Hubei, Kina, 430030
- Har inte rekryterat ännu
- Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Kontakt:
- Qin Ning, Prof.
- Telefonnummer: 862883662391
- E-post: qning@vip.sina.com
-
Huvudutredare:
- Qin Ning, Doctor
-
Huvudutredare:
- Di Wu, Doctor
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Males and non-pregnant, non-lactating female patients with HBsAg positive > 6 months above 18 years of age; Documented evidence of chronic HBV infection previously; HBV mono-infected HBeAg positive or negative; NA treatment-naive and treatment-experienced; TAF naive; Agree to participate in the study and sign the patient informed consent.
Subjects coinfected with HCV, hepatitis D virus (HDV), human immunodeficiency virus (HIV) or who have received TAF or who haveChild-Pugh C decompensated liver disease or HCC will be excluded.
Beskrivning
Inclusion Criteria:
- Must have the ability to understand and sign a written informed consent form, consent must be obtained prior to initiation of study procedures
- Adult males and nonpregnant, nonlactating females
- Documented evidence of chronic HBV infection previously
- TAF naive
Exclusion Criteria:
- Patents who were TAF experienced
- Women who are breastfeeding
- Pregnant females
- Co-infection with hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV
- Evidence of hepatocellular carcinoma (Note: if screening alpha-fetoprotein (AFP) is < 50 ng/mL no imaging study is needed; however, if the screening AFP is > 50 ng/mL an imaging study is required)
- Chronic liver disease of non-HBV etiology (e.g., hemochromatosis, fatty liver disease, cholangitis)
- Current evidence of Child-Pugh Score C decompensated liver disease,or moderate to severe ascites, Grade III-IV hepatic encephalopathy
- Abnormal hematological and biochemical parameters, including:
- Albumin < 2.8 mg/ dL
- International normalized ratio (INR) > 2.3 X ULN (unless stable on anticoagulant regimen)
- Total bilirubin > 3 X ULN
- Patient develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity
- Received solid organ or bone marrow transplant, except patients who underwent liver or kidney transplantation
- Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (e.g., basal cell skin cancer). Individuals under evaluation for possible malignancy are not eligible.
- Individuals receiving ongoing therapy with drugs not to be used with TAF or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients
- Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements
- Use of investigational agents within 3 months of screening, unless allowed by the sponsor
- Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening
- Current alcohol or substance abuse judged by the investigator to potentially interfere with compliance
- Inability or unwillingness to provide informed consent or abide by the requirements of the study
- In addition to the above exclusion criteria, patients who meet any of the contraindications for TAF
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Tenofovir alafenamide (TAF)
Male or female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with anti-HBV agents.
|
The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
proportion of participants with HBV DNA < 20 IU/mL
Tidsram: 36 months
|
proportion of participants with HBV DNA < 20 IU/mL as measured by the COBAS TaqMan HBV Test (Roche Molecular Diagnostics, Pleasanton, CA, USA), with taken at 36 months
|
36 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The proportion of patients with HBV DNA < 20 IU/mL
Tidsram: 12 months
|
The proportion of patients with HBV DNA < 20 IU/mL at 12 months
|
12 months
|
The proportion of patients with HBV DNA <300 copies/mL
Tidsram: 12 months
|
The proportion of patients with HBV DNA <300 copies/mL at 12 months
|
12 months
|
The proportion of patients with HBV DNA < 20 IU/mL
Tidsram: 24 months
|
The proportion of patients with HBV DNA < 20 IU/mL at 24 months
|
24 months
|
The proportion of patients with HBV DNA <300 copies/mL IU/mL
Tidsram: 24 months
|
The proportion of patients with HBV DNA <300 copies/mL at 24 months
|
24 months
|
The proportion of patients with HBV DNA <300 copies/mL IU/mL
Tidsram: 36 months
|
The proportion of patients with HBV DNA <300 copies/mL at 36 months
|
36 months
|
Proportion of participants with Hepatitis B e Antigen (HBeAg) Loss
Tidsram: 36 months
|
Proportion of participants with Hepatitis B e Antigen (HBeAg) Loss at 36 months
|
36 months
|
Proportion of participants with seroconversion to Anti-Hepatitis B e-Antigen (Anti-HBe)
Tidsram: 36 months
|
Proportion of participants with seroconversion to Anti-Hepatitis B e-Antigen (Anti-HBe) at 36 months
|
36 months
|
Proportion of participants with Normal Alanine Aminotransferase (ALT)
Tidsram: 36 months
|
Proportion of participants with Normal Alanine Aminotransferase (ALT) at 36 months
|
36 months
|
Change from baseline in fibrosis as assessed by Fibroscan®
Tidsram: 36 months
|
Change from baseline in fibrosis as assessed by Fibroscan® at 36 months
|
36 months
|
Percent Change from baseline in Bone Mineral Density (BMD)
Tidsram: 36 months
|
Percent Change from baseline in Bone Mineral Density (BMD) at 36 months
|
36 months
|
Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG)
Tidsram: 36 months
|
Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG) at 36 months
|
36 months
|
the rate of mother-to-child transmission of HBV
Tidsram: at postpartum 6 months
|
For unplanned pregnant subjects, if not withdrawn, mother-to-child transmission (MTCT) rate
|
at postpartum 6 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Qin Ning, MD., Ph.D., Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Leversjukdomar
- Hepatit, Viral, Human
- Hepadnaviridae-infektioner
- DNA-virusinfektioner
- Hepatit B
- Hepatit
- Hepatit B, kronisk
- Hepatit, kronisk
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Omvända transkriptashämmare
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Tenofovir
Andra studie-ID-nummer
- IN-US-320-4669
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kronisk hepatit b
-
Clínica de Oftalmología de Cali S.AAvslutadMeibomisk körteldysfunktion | Eyes Dry ChronicColombia
-
AstraZenecaCLL ConsortiumAvslutadB-cellslymfom | 11q-deleted Relapsed/Refractory Chronic Lymfocytic Leukemi (KLL), | Prolymfocytisk leukemi (PLL)Förenta staterna
-
Alcon ResearchAvslutad
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekryteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Dhulikhel HospitalKathmandu University School of Medical SciencesIndragenPostoperativ analgesi | CSOM - Chronic Suppurative Otitis MediaNepal
-
Occyo GmbHUniversity Clinic for Ophthalmology and Optometry- SalzburgAvslutadLimbal stamcellsbrist | Hornhinnas sjukdom | Eyes Dry Chronic | Kronisk konjunktivit i båda ögonen | Ögonskada | Ögonsjukdom; Grå starr | Ögon torr känsla av | Hornhinnan inflammerad | Hornhinna; Skada, nötning | Hornhinna infektionÖsterrike
-
Nathan DenlingerBristol-Myers SquibbRekryteringB-cells non-Hodgkin lymfom - återkommande | Diffust stort B-cellslymfom - återkommande | Follikulärt lymfom - återkommande | Höggradigt B-cellslymfom - återkommande | Primärt mediastinalt stort B-cellslymfom - återkommande | Transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort... och andra villkorFörenta staterna
-
Northwestern UniversityNational Cancer Institute (NCI)Aktiv, inte rekryterandeDiffust stort B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Höggradigt B-cellslymfom, ej specificerat på annat sätt | T-cell/Histiocyt-rik stort B-cellslymfom | Höggradigt B-cellslymfom med MYC och BCL2 och/eller BCL6 omarrangemang | Diffust stort B-cellslymfom aktiverat... och andra villkorFörenta staterna
-
Nanfang Hospital of Southern Medical UniversityRekryteringB-cellslymfom | B-cells akut lymfoblastisk leukemi | B-cellsleukemi | B-cellslymfom refraktär | B-cellslymfom ÅterkommandeKina
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeÅterkommande diffust stort B-cellslymfom aktiverat B-cellstyp | Refraktärt diffust stort B-cellslymfom aktiverat B-cellstypFörenta staterna, Saudiarabien
Kliniska prövningar på Tenofovir Alafenamide
-
SpectraCure ABRekryteringÅterkommande prostatacancerFörenta staterna, Kanada, Storbritannien, Sverige
-
University Hospital Inselspital, BerneAvslutad
-
Kaohsiung Medical University Chung-Ho Memorial...OkändHepatit B | Fibros och levercirrosTaiwan
-
University Health Network, TorontoGilead Sciences; University of Modena and Reggio Emilia; San Raffaele University... och andra samarbetspartnersAvslutad
-
Thomas Jefferson UniversityGilead SciencesAktiv, inte rekryterande
-
Thomas Jefferson UniversityAvslutadHyperglykemi | Hjärt-kärlsjukdomar | Metaboliskt syndrom | Viktökning | HIV-1-infektion | Onormal njurfunktionFörenta staterna
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)AvslutadMalign fast neoplasma | Hepatit B-infektionFörenta staterna, Guam
-
University Health Network, TorontoRekrytering
-
Stanford UniversityGilead SciencesAvslutadHepatit B, kroniskFörenta staterna, Taiwan, Japan, Korea, Republiken av
-
National Taiwan University HospitalOkändHepatit B-virusinfektionTaiwan